Physician profile
Daniel S Merrick
NPI 1184680654
$14,526.92
in general payments reported to CMS, 2019-2025
41 companies · $467 in 2025
The $467 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $3,384 · 2021: $5,048 · 2022: $1,556 · 2023: $1,920 · 2024: $681 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011 · Travel and Lodging: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,011.05 |
| Travel and Lodging | $1,056.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,204.75 | 2019-2025 | |
| Procept Biorobotics Corporation | $1,342.39 | 2022-2025 | Aquabeam Robotic System |
| Janssen Biotech, INC. | $673.36 | 2019-2024 | Erleada, Akeega, Balversa |
| Astellas Pharma US INC | $564.83 | 2019-2025 | Xtandi |
| Olympus America INC. | $543.48 | 2022-2025 | Bovie, Olympus, Itind System |
| Axonics, INC. | $394.77 | 2022-2024 | Axonics, Bulkamid |
| Dendreon Pharmaceuticals LLC | $359.56 | 2019-2025 | Provenge |
| Antares Pharma, INC. | $346.35 | 2019-2022 | |
| Travere Therapeutics, INC. | $175.65 | 2021 | |
| Pfizer INC. | $158.84 | 2019-2025 | |
| Blue Earth Diagnostics | $145.75 | 2022-2024 | |
| Angiodynamics, INC. | $142.49 | 2022 | |
| Merck Sharp & Dohme LLC | $142.23 | 2019-2023 | Lynparza, Keytruda |
| Boston Scientific Corporation | $130.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.72 | 2023 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, LP | $99.99 | 2019 | |
| Myriad Genetic Laboratories, INC. | $84.38 | 2020-2024 | Prolaris |
| Sumitomo Pharma America, INC. | $83.75 | 2023 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $76.45 | 2020-2022 | |
| Allergan, INC. | $67.69 | 2019-2021 | |
| Verity Pharmaceuticals INC. | $67.40 | 2022-2024 | Trelstar |
| Amgen INC. | $66.00 | 2022-2023 | Xgeva |
| Tolmar Pharmaceuticals, INC. | $65.77 | 2019-2022 | |
| Urovant Sciences INC | $49.36 | 2022 | |
| Novartis Pharmaceuticals Corporation | $49.23 | 2025 | |
| Covidien LP | $41.77 | 2020 | |
| Halozyme INC | $41.65 | 2023 | |
| C. R. Bard, INC. & Subsidiaries | $41.15 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $31.59 | 2023 | Seglentis |
| Endo Pharmaceuticals INC. | $31.03 | 2019-2023 | Xiaflex, Aveed |
| Progenics Pharmaceuticals, INC. | $28.81 | 2022 | |
| Tempus Ai, INC | $27.85 | 2024 | |
| Endo USA, INC. | $22.80 | 2025 | Xiaflex |
| Accord Healthcare, INC. | $22.21 | 2022 | |
| Tolmar, INC. | $22.01 | 2023 | |
| Clarus Therapeutics INC. | $20.22 | 2021 | |
| Cardinal Health 414 LLC | $18.87 | 2023 | |
| Cook Medical LLC | $17.46 | 2019 | |
| Dentsply Ih INC. | $11.10 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Merrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.